Related Experiment Video
Updated: Jun 30, 2025
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.2K
Defining Parkinson's Disease: Past and Future.
Kristina Kulcsarova1,2,3, Matej Skorvanek1,2, Ronald B Postuma4
1Department of Neurology, P. J. Safarik University, Kosice, Slovak Republic.
Journal of Parkinson'S Disease
|March 15, 2024
Summary
Parkinson's disease (PD) diagnosis is shifting from clinical symptoms to biological markers. Early detection through α-synuclein, neurodegeneration, and genetics aims for future disease-modifying therapies.
Area of Science:
- Neurology
- Neurodegenerative Diseases
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Current diagnostic criteria rely on late-stage motor symptoms, delaying intervention.
- Understanding PD pathophysiology is crucial for early detection.
Purpose of the Study:
- To review the evolution of Parkinson's disease definitions.
- To advocate for a shift towards a biological definition of PD.
- To explore early diagnostic markers for potential disease-modifying therapies.
Main Methods:
- Literature review of PD diagnostic criteria and advancements.
- Analysis of emerging biological markers for PD.
- Discussion of the application of these markers in a biological PD definition.
Main Results:
- Historical PD definitions were based on clinical motor signs.
- A paradigm shift towards biological definitions is underway.
- Key pillars for biological PD definition include α-synuclein aggregation, neurodegeneration, and genetics.
Conclusions:
- A biological definition of PD, similar to Alzheimer's and Huntington's diseases, is proposed.
- In vivo detection of specific markers can enable earlier PD diagnosis.
- Early diagnosis is essential for developing and applying disease-modifying treatments.
Related Concept Videos
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:26Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K